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ABSTRACT
Diffuse large B cell lymphoma (DLBCL), the most common subtype of aggressive lymphoma, has considerable
biologic and clinical heterogeneity. Despite recent therapeutic advances, up to 50% of patients relapse after stan-
dard chemoimmunotherapy. The International Prognostic Index (IPI) at relapse is of value in providing prognos-
tic information on response to salvage chemotherapy and outcome after autologous hematopoietic cell
transplantation (aHCT). Predictive biologic and gene expression markers, however, remain undefined, and re-
quire further clarification from additional molecular studies. To date, the standard of care in the management
of relapsed/refractory DLBCL is salvage chemotherapy followed by an aHCT for those with chemotherapy-sen-
sitive disease. Currently, there is no standard salvage chemotherapy regimen, and the use of immunotherapy for
relapsed disease requires further evaluation. This review focuses on prognostic markers, current salvage thera-
pies, and discusses the role of novel treatment in the management of relapsed/refractory DLBCL.
 2008 American Society for Blood and Marrow Transplantation
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Diffuse large B cell lymphoma (DLBCL), the most
common subtype of non-Hodgkin lymphoma (NHL),
is an aggressive disease with considerable biologic and
clinical heterogeneity. Standard first-line treatment is
combination chemotherapy with cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) or
an equivalent regimen combined with rituximab (R).
This results in a complete remission (CR) rate of
75%-80% [1,2] and a 3-5-year progression-free sur-
vival (PFS) of 50%-80% [1,2]. The addition of R to
CHOP chemotherapy has been the most significant
step in recent years to improving overall survival
(OS) and PFS rates. Current treatment with CHOP-
R results in an improvement in PFS and OS by 15%-
20% over CHOP chemotherapy alone [1-3].
Despite thismajor therapeutic advance, a significant
proportion of patients will relapse or remain refractory
to initial chemoimmunotherapy. The PARMA trial
confirmed the place of high-dose chemotherapy and au-
tologous hematopoietic cell transplantation (aHCT) as
the optimum salvage treatment. In this trial, chemo-
therapy-sensitive patients were randomized to furthersalvage chemotherapy with cytarabine/platinum-based
chemotherapy alone, or in combination with aHCT.
Event-free survival (EFS) andOS at 5 years in the trans-
plant arm were 46% and 53%, respectively, compared
with 12% and 32% in the chemotherapy alone arm
[4]. Response to salvage chemotherapy is a very impor-
tant predictor of outcome following aHCT: patients
sensitive to salvage chemotherapy have a 5-year PFS
of 43% versus 1-year survival of 22% for those who
are chemotherapy resistant [5-7]. Despite the impor-
tance of response to salvage chemotherapy, there is no
consensus as to the most effective regimen prior to
aHCT, as all published data to date have been from
nonrandomized studies.
This review provides an evidence-based approach
to evaluate prognosis and management of patients
with relapsed/refractory DLBCL focusing on the
available salvage chemotherapy regimens.
Prognostic Factors at Relapse
International Prognostic Index. The Interna-
tional Prognostic Index (IPI) [8] is a validated scoring
system to predict the survival rate of patients with259
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setting of relapsed or refractory disease, the IPI at
commencement of salvage therapy is predictive for
OS and PFS. In an analysis of the PARMA trial,
Blay et al [9] demonstrated that the IPI correlated
with OS in patients treated with chemotherapy alone
but not with aHCT. There was considerable hetero-
geneity with respect to disease and patient-related fac-
tors in this trial and a limited numbers of patients with
higher IPI scores, which may explain the lack of cor-
relation between IPI and survival in patients undergo-
ing aHCT. Two other studies, both cohort analyses,
demonstrate a correlation between the age adjusted
IPI and prognosis in relapsed patients undergoing
aHCT. Hamlin et al [10] found that patients with
a second-line age-adjusted IPI of 0 had a 4-year PFS
and OS of 69% and 83%, respectively, versus 25%
and 26% for an IPI of 2 or 3. A similar observation
was made in an Italian study of over 400 patients
(treated with chemotherapy alone or in conjunction
with aHCT) in which the same factors (advanced
stage, elevated lactate dehydrogenase and poor per-
formance status) for the age-adjusted IPI as well as
time to relapse were associated with an adverse
response to salvage chemotherapy/aHCT. Interest-
ingly, advanced age was not found to be a prognostic
factor at relapse; however, 80% of the cohort was
treated with chemotherapy alone, and this low pro-
portion of young adults receiving aHCT may have
obscured the prognostic value of age [11].
Positron emission tomography. Fluorine-18-de-
oxyglucose positron emission tomography (PET) has
the advantage over conventional computed tomogra-
phy (CT) scanning to distinguish between fibrosis
and active tumor. In newly diagnosed patients treated
with conventional chemotherapy, residual masses on
CT at the end of chemotherapy are not very predictive
of relapse [12]. In contrast, when performed 6-8 weeks
after the last cycle of chemotherapy [13], a positive
PET scan has a very high positive predictive value
for disease relapse [14,15].
Similar findings are evident in patients with
DLBCL, who have relapsed after primary treatment.
Residual masses are frequently detected by CT after
salvage chemotherapy, and these are not predictive of
outcome after aHCT [16,17]. In contrast, several stud-
ies show that PET scanning, performed after salvage
chemotherapy, is predictive of outcome after aHCT
[16,18], independent of the second-line age-adjusted
IPI [19]. Patients achieving a CR on PET scan after
salvage chemotherapy have a 75% failure-free survival
at 2 years compared with 40% for patients who achieve
a partial remission (PR) on PET [16,19]. Furthermore,
outcome is better with early normalization of PET (af-
ter limited courses of salvage chemotherapy) compared
with patients who normalize their PET scans only after
multiple cycles of salvage chemotherapy [20].Biomarkers. In de novo DLBCL, an array of bio-
markers have been evaluated, many of which have
prognostic implications. One of the most important
biologic analyses that has been developed is gene ex-
pression profiling. This has led to the division of de
novo DLBCL into germinal and nongerminal sub-
types based on the relative expression of normal germi-
nal center B cell genes [21]. The germinal center
DLBCL subtype is usually BCL6, CD10-positive,
and MUM 1 negative [21,22], and a simplified method
using immunohistochemistry to these markers (as op-
posed to using tissue microarray) to subtype DLBCL
has been proposed [22]; however, the validity of this
method is debated [23]. Germinal center DLBCL sub-
type has a better survival and fewer relapses after
chemotherapy compared with a nongerminal center
phenotype (76% versus 16% 5-year survival) [21].
Genes involved with regulating B cell signaling,
serine/threonine phosphorylation pathways, and apo-
ptosis such as VEGF, PKC, and PDE4B, are also over-
expressed in patients with DLBCL who have an
adverse outcome [24].
In contrast to its predictive value in newly diag-
nosed patients, categorizing patients into germinal
versus nongerminal subtypes may not have prognostic
value in relapsed patients [25]. The cell of origin was
evaluated using immunohistochemistry in 88 trans-
plant-eligible patients with relapsed DLBCL planned
to undergo ICE (ifosfamide, carboplatin, and etopo-
side) salvage chemotherapy. Sixty patients had a non-
germinal center subtype by this method. The patient
characteristics of this group, including IPI and age,
were similar to the 28 patients with a germinal center
subtype. There was no difference in response to ICE
chemotherapy or OS based on cell of origin. Further-
more, other molecular markers including MIB 1,
MUC 1, MDR, p53, and BCL 2 had no prognostic
role [26]. Conversely, in a small number of patients,
Haarer et al [27] reported better survival for patients
with a germinal center subtype, although treatment
at relapse was not described. Additional information
about expression of drug resistance proteins and path-
ways is needed to understand these observations [28].
There is limited research to date assessing progno-
sis of relapsed/refractory DLBCL with biomarkers.
Moreover, it appears that once DLBCL has relapsed
undefined biologic entities play a dominant role in de-
termining response to therapy.Whether these markers
evolve in the relapsed state and reflect ongoing disease
remodeling or are present at diagnosis but are yet un-
defined, is uncertain.
With our current knowledge of DLBCL, patients
with a nongerminal subtype or those who overexpress
VEGF/PKC and PDE4B are less likely to be cured
with CHOP based chemotherapy [24]. Consequently,
targeting these pathways may improve the success of
salvage therapy.
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Numerous salvage chemotherapy regimens have
been used to treat relapsed or refractory DLBCL.
The majority are based on agents that demonstrate
noncrossresistance to those used in primary therapy.
Broadly speaking, they can be divided into regimens
based on ifosfamide, cytarabine /platinum, or gemcita-
bine. Studies on salvage therapy have generally in-
cluded all patients with aggressive lymphoma and are
not restricted to DLBCL subtype. An ideal salvage
therapy regimen for use prior to aHCT should have
a high response rate, low hematologic, and nonhema-
tologic toxicity, and not impair the ability to mobilize
peripheral blood stem cells (PBSC).
Ifosfamide-containing regimens. Ifosfamide-based
regimens have been used to treat lymphomas for over 10
years [29,30]. This analogue of cyclophosphamide (CY)
is included in many salvage regimens because data sug-
gest that it is partially noncrossresistant with CY [31].
Furthermore, it can be used in high doses with minimal
toxicity.Many ifosfamide-based chemotherapy regimens
have been used to treat relapsed/refractory lymphoma.
Most regimens include etoposide and additional agents
such as platinum, methotrexate, cytarabine, or dexa-
methasone. Studies of these regimens show that stem
cell collection is adequate in the vast majority of patients
[7,32]. Toxicity of these regimens is mainly hematologic.
Grade 4 neutropenia occurs in 50%-70% [7,33] of cases
and hospitalization for febrile neutropenia occurring in
10%-20%of cases [32,34].Grade 3 or 4 thrombocytope-
nia occurs in 30%-90% [7], and 40%-55% of patients
will require at least 1 red cell transfusion [32,33].Nonhe-
matologic toxicity appears to be mild to moderate in
most cases, with nausea the most common side effect
[35]. Significant genitourinary toxicity is rare if mesna
is concurrently administered [32-34]. Neurotoxicity in
the form of confusion is seen in\5% of cases [29,32].
Cytarabine/platinum-containing regimens. Sin-
gle-agent high-dose cytarabine can induce transient
remissions in patients whose lymphoma is refractory
to other regimens [36]. It is a pyrimidine antimetabo-
lite that is converted to the active form, cytarabine
triphosphate, after entry into the cell. Cytarabine tri-
phosphate hinders DNA synthesis by inhibiting
DNA polymerase, and creates chromosomal breaks
by incorporating itself into the genomic DNA [36].
Regimens containing platinum and cytarabine were
developed after platinum was noted to have in vitro
synergistic effects with cytarabine in colonic cancer
cell lines. These include DHAP (cisplatin, cytarabine,
and dexamethasone) [37], ESHAP (etoposide, Solu-
medrol, cytarabine, and cisplatin) [38], and ASHAP
(doxorubicin, Solumedrol, cytarbine, and platinum)
[39]. Both ASHAP and ESHAP are infusional
regimens.Toxicities are predominantly hematologic, with
grade 4 neutropenia and thrombocytopenia occurring
in 50%-74% and 40%-60% of patients, respectively
[40,41]. Red cell or platelet transfusion are required
in up to 70% of patients [42]. Nonhematologic toxic-
ities include mild to moderate nausea, vomiting, and
diarrhea [39]. Significant nephrotoxicity is infrequent,
occurring\5% of the time [38,41,43]. Replacing cis-
platin with oxaliplatin does not significantly alter the
response rates or toxicity profile [44].
Fludarabine enhances the cytotoxicity of both cy-
tarabine and cisplatin by increasing the cytarabine in-
corporation into genomic DNA and by inhibiting
repair of platinum adducts. Trials of fludarabine con-
taining regimens in primary refractory or refractory
recurrent NHL showed encouraging results, with an
overall response rate of 39% in this poor prognosis
group. However, only 44% of patients obtained an ad-
equate stem cell collection, presumably because of the
inclusion of fludarabine [45,46]. The exact mechanism
of impaired stem cell mobilization from fludarabine
remains to be defined.
Gemcitabine-containing regimens. Gemcitabine
is a pyrimidine antimetabolite with structural similari-
ties to cytarabine. Like cytarabine, it is metabolized to
its active form, gemcitabine triphosphate once inside
the cell membrane. DNA chain elongation is inhibited,
and consequently, DNA synthesis is impaired, with
a subsequent increase in apoptosis. This agent has
a long history of success in solid tumors and a highly
favorable toxicity profile. In relapsed or refractory
DLBCL the activity of single agent gemcitabine is
approximately 20% [47]. Gemcitabine-containing regi-
mens used in relapsed or refractory aggressive lym-
phoma include combinations with vinorelbine [48,49]
or cisplatin based on in vitro data showing synergy be-
tween the latter agents [50-52]. Hematologic toxicities
again predominate in these regimens, although appear
less frequent compared with ifosfamide or cytarabine
combinations. Grade 4 neutropenia occurs in 20%-
30% of patients, and grade 4 thrombocytopenia or
anemia occurs in 10%-25% and 2%-5% of patients,
respectively [48,50,52].
Other regimens. Other salvage regimens are used
for relapsed/refractory aggressive lymphoma, but it is
not possible to mention them all in this review.
Some, such as mini-BEAM (BCNU, etoposide, cytar-
abine, and melphalan), demonstrate good response
rates when used prior to aHCT; however, they are
associated with profound myelotoxicity [53] and
impaired stem cell collection [54]. Salvage chemother-
apy regimens that contain previously used agents can
also produce acceptable response rates. EPOCH
(etoposide, vincristine, doxorubicin, CY, and prednis-
olone) is an example whereby changing the administra-
tion of the drugs from a bolus to a prolonged infusion
can result in responses of up to 70%-80% in relapsed
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men was developed based on data demonstrating that
tumor cells display increased sensitivity to prolonged
rather than brief high levels of exposure. Major toxic-
ities include moderate to severe neutropenia and
thrombocytopenia in 50% and 24%, respectively,
and significant peripheral neuropathy requiring dose
reduction of vincristine in 10%. Moderate or severe
cardiac toxicity occurred in only 3% of patients despite
94% of the cohort having had prior anthracycline ex-
posure [56].
Salvage Chemotherapy When Used with aHCT
Results of various salvage chemotherapy regimens
used in the context of aHCT are presented in Table 1.
Only studies of .20 patients with intermediate/ag-
gressive histology undergoing aHCT retrieved from
PubMed are included. In most of these trials, assess-
ment of disease occurred after 2-3 cycles of salvage
chemotherapy. Because these are phase II trials, mean-
ingful comparisons between them are not possible be-
cause of differences in baseline patient characteristics,
methods of disease assessment, and the timing of as-
sessment. However, it is apparent that a considerable
proportion of patients do not respond to salvage che-
motherapy, and those who do, are more likely to ob-
tain a partial rather than a complete remission.
When otherwise transplant-eligible patients fail to
respond to salvage chemotherapy the utility of trying
a different regimen is not well studied. One study re-
ported a response rate of 32% for patients receivinga second-line salvage therapy [57]. This series in-
cluded multiple histologies (Hodgkin lymphoma, in-
dolent NHL, and aggressive NHL), and 1/3 of
patients included had a partial response to first-line
salvage therapy. The second series [58], evaluated
ICE chemotherapy in 21 patients with relapsed/re-
fractory DLBCL who had stable or progressive dis-
ease following DHAP chemotherapy, and reported
a response rate of 52%. When patients respond to
second-line savage chemotherapy undergo aHCT,
5-year disease-free survival (DFS) of 23% has been re-
ported [59].
Rituximab and Salvage
The mechanisms by which R, a monoclonal anti-
body (mAb) directed toward CD20, exert its antitumor
effects include antibody and complement-dependent
cytotoxicity resulting in reduced cell proliferation. In-
duction of apoptosis also occurs via downregulation of
antiapoptotic pathways such as BCL-2, NF-kB, and
ERK [60], and in primary therapy the use ofR can over-
come the negative prognostic influence of BCL-2 over-
expression [61]. It is not know whether the same
cellular mechanisms for R apply in the relapsed setting.
In the absence of previous R therapy, the addition
of R to salvage regimens such as ICE (RICE) orDHAP
generates more complete remissions at the time of
aHCT compared with the use of chemotherapy alone.
Kewalramani et al [34] reported a 58% CR with RICE
in 34 patients with relapsed/refractory DLBCL com-
pared to 27% in historic controls treated with ICETable 1. Studies of Salvage Therapy Regimens in Relapsed/Refractory Aggressive NHL undergoing aSCT
Salvage Rx Ref
Number of
Patients
with
Aggressive
NHL
Number
Transplanted
Relapsed/
Refractory (%)
ORR
(%)
CR/PR
(%)
OS
(in Transplanted pts)
PFS
(in transplanted pts)
GDP  2 50 51 26 92/8 49 16/33 NS NS
ESAHP  3 42 65 23 37/63 62 NS 45% at 5 years NS
ICE  3 32 163 96 52/48 66 24/42 65% at 3 years if had
CR, 30% if had PR
54% (CR),
29% (PR) at
3 years
RICE  3 34 36 24 64/36 78 53/25 67 % at 2 years 54% at 2 years
DHAP  2 43 28 23 69/31 68 29/39 39% at 4 years 35% at 4 years
DHAP  2 4 215 54 100/0 58 NS 53% at 5 years 46% at 5 years
mini BEAM  2-3 53 104 38 48/52 37 25/12 36% at 3 years NS
R-DHAP-VIM-DHAP 62 101 77 NS 77 NS 62% at 2 years 82% at 2 years
DHAP-VIM-DHAP 62 101 49 NS 49 NS 48% at 2 years 46% at 2 years
DHAP  2 37 57 41 60/40 72 9/63 47% at 2 years (all pts) 25% (all pts)
IVAD  2 7 59 NS 90/10 75 19/56 43% at 5 years
for IVAD responders
NS
NS indicates not stated; GDP, gemcitabine 1000 mg/m2 d1,8, dexamethasone 40 mg d1-4, cisplatin 75 mg/m2 d1;
(R)ICE, (rituximab 375 mg/m2 d1), ifosfamide 5 g/m2 d2, carboplatin AUC under 5 d2, etoposide 100 mg/m2 d1-3;
DHAP, dexamethasone 40 mg d1-4, cytarabine 2 g/m2 q12h d2, cisplatin 100 mg/m2 d1; ESHAP, etoposide 40 mg/m2 d1-4, cisplatin 25 mg/m2
d1-4, cytarabine 2 g/m2 d4, methylprednisolone 500 mg d1-4; MiniBEAM, busulphan 60 mg/m2 d1, etoposide 75 mg/m2 d2-5, cytarabine
100 mg/m2 q12h d2-5, melphalan 30 mg/m2 d6; IVAD, Ifosfamide 1.5 g/m2 d1-5, etoposide 100 mg/m2 d1-5, cytarabine 100 mg/m2 d1-5,
dexamethasone 40mg d1-5; pts, patients; CR, complete remission; PR, partial remission; PFS, progression-free sruvival; OS, overall survival;
NHL, non-Hodgkin lymphoma; ORR, overall response rate.
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analysis of the GELA trial in patients over 60 years
of age with DLBCL undergoing primary therapy
with CHOP or CHOP-R, 50% (n 5 202) relapsed
and 185 had salvage therapy. Because of limited avail-
ability, R-based salvage regimens were administered to
only 31 patients. Survival based on R use in salvage
therapy was analyzed and found that those receiving
R had a significantly improved survival (58% at 2
years) versus 24% for those who did not; P5.00067 [1].
The HOVON group recently published in ab-
stract form the result of their prospective randomized
study in which the addition of R was compared to
salvage chemotherapy alone in patients eligible for
aHCT. Two hundred two patients with relapsed/re-
fractory CD201 aggressive NHL after anthracy-
cline-based chemotherapy were randomized to
DHAP-VIM-DHAP or R-DHAP-VIM-DHAP. In
addition to improved overall response rate (77% ver-
sus 49%) to salvage chemotherapy, failure-free sur-
vival following aHCT was also improved in patients
assigned to R (52% versus 21%, P\.001) [62]. Of
note, prior R use was not mentioned.
Data on the efficacy of R retreatment are sparse. It
is apparent that some patients can acquire R resistance
possibly through the hyperactivation of ERK1/2 and
NF-kB pathways and from overexpression of BCL-2
[60]. In the GELA trial, the benefit of adding R to sec-
ond-line therapy was statistically significant in patients
who had CHOP as initial treatment, but significance
was not reached in patients who had R-CHOP as pri-
mary therapy [1]. However, in this trial only 9 patients
received upfront and second-line R; thus, it is impossi-
ble to draw any conclusion as to the benefit of R added
to salvage regimens when there has been prior use.
It appears, therefore that the impact of R in the sal-
vage setting is considerable when there has been no
prior exposure. However, given that the majority of
patients with DLBCL receive R as part of their initial
therapy, its benefit in salvage regimens remains to be
defined.
Radioimmunoconjugates
Radioimmunoconjugates (RIC) such as 90Y ibritu-
momab tiuxetan (Zevalin) and 131I tositumomab (Bex-
xar) harness the targeting powers of murine anti-CD20
to deliver cytotoxic radiation to tumor cells. These
agents have been shown to be active in B cell low-grade
lymphoma, but data on DLBCL are limited. In the
palliative setting, 90Y ibritumomab tiuxetan has been
trialed in 104 patients with relapsed or refractory
DLBCL who were ineligible for transplant. Twenty-
six patients had received prior R and were analyzed
separately. Response rates were significantly better
for those who had not received R (58%) compared
with those that had (19%). The reason behind thepoor response in R-exposed patients is unclear, as
this agent is active in patients with follicular lymphoma
with prior R exposure. One possible explanation is that
failing R-CHOP is amarker for refractory disease [63].
90Y ibritumomab tiuxetan has also been given with
high-dose CY and etoposide followed by autologous
hematopoietic cell reinfusion in relapsed/refractory B
cell NHL. There was no additional transplantation-
related toxicity with this approach and 2-year re-
lapse-free survival and OS for the DLBCL patients
was 74% and 93%, respectively [64]. Similarly, 131I to-
situmomab tiuxetan has been combined with BEAM
(BCNU, etoposide, cytarabine, and melphalan) che-
motherapy in chemotherapy-resistant B cell NHL pa-
tients. Toxicity was not increased over that of standard
BEAM aHCT, with EFS and OS at 39% and 55% at 3
years [65]. Myleoablative doses of 131I tositumomab
tiuxetan has also been evaluated in conjunction with
aHCT in elderly patients with relapsed B cell NHL.
In this phase II study, 24 patients, 9 of whom had
DLBCL, the estimated 3-year OS and PFS was 56%
and 37%, respectively, and no treatment-related
deaths were recorded [66]. Prior R use was not
mentioned.
These initial reports are encouraging in that RIC
can be combined with current treatment modalities
[67]. However, further studies are required to evaluate
the optimal way to administer RIC. Given that in vivo
xenogeneic murine models of DLBCL have demon-
strated synergy between 131I tositumomab tiuxetan
and agents such as bortezomib [68], it may be possible
to enhance the cytotoxic effects of RIC using combina-
tion therapy. Furthermore, because most patients will
receive R as part of their upfront therapy, the use of
RIC, either as part of myeloablative therapy, or with
salvage/second-line chemotherapy, needs further
evaluation.
New Directions
Two phase III trials, that aim to guide salvage che-
motherapy choice in DLBCL in patients eligible for
aHCT, are in progress. TheCORAL study [69], amul-
ticenter trial based in Europe, is comparing R-DHAP
to R-ICE in transplant-eligible patients with relapsed
DLBCL, whereas the NCI Canadian Ly-12 study is
comparing R-GDP toR-DHAP as salvage chemother-
apy in patients with aggressive NHL undergoing
aHCT. Both trials will have a second randomization
of patients completing aHCT to Rmaintenance versus
observation alone. The purpose of these trials is to
evaluate the response rate to salvage chemotherapy
and the ability to proceed to aHCT. Moreover, be-
cause of the time period for recruitment, a substantial
number of patients will have had R as part of primary
therapy, and therefore the efficacy of subsequent R
therapy will also be examined.
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other potential therapeutic targets such as protein
kinase C. Protein kinase C modulates downstream
signaling via the NF-kB survival pathway in B cells,
and it also modifies VEGF signaling in the tumor mi-
crovasculature [70]. A protein kinase C inhibitor, en-
zastaurin, has been trialed in relapsed or refractory
DLBCL. In a phase II study of 55 patients who had
a median number of 2 prior therapies, treatment with
enzastuarin was found to be well tolerated, and re-
sulted in 8 patients remaining free from progression
for .4 cycles of therapy [71].
The notion that tumor angiogenesis plays a role in
the pathogenesis of DLBCL is further supported by
the finding that VEGF gene expression is more com-
mon in patients with a nongerminal and refractory
center B cell lymphoma [24]. An antibody to VEGF,
bevacizumab, has been trialed in this patient group.
Bevacizumab has been approved in metastatic colon
cancer, and increases response rates with conventional
chemotherapy in solid tumors. Single agent bevacizu-
mab has shown to be well tolerated, and has a clinical
nonprogression rate of 25% in a phase II study of pa-
tients with relapsed aggressive NHL [72]. Bevacizu-
mab has also been safely combined with conventional
chemotherapy [73].
Chromatin remodeling is another potential thera-
peutic target that has been investigated in DLBCL.
Histone deactetyltransferase (HDAC) is an enzyme
that removes acetyl groups from chromatin and thus
allows cellular DNA to remain tightly wound around
histone proteins. This results in downregulation of
transcription and leads to cellular quiescence. Drugs
that inhibit HDAC can result in a more transcription-
ally active cell leading to cell differentiation and
apoptosis. Two pathways involved in DLBCL patho-
genesis, BLC-6 and p53, are downregulated by acety-
lation [70]; however, the HDAC enzyme removes this
suppression, thereby upregulating these survival path-
ways. Hence, inhibiting deacetylation by pharmaco-
logic methods may result in suppression of both the
p53 and BCL-6 pathways, providing a rationale for
these agents in DLBCL [70]. There are 4 classes of
HDAC inhibitors, and these agents show activity in
hematologic malignancies and solid tumors in phase
I trials [74]. Several agents are under current investiga-
tion in relapsed/refractory DLBCL.
CONCLUSION
Other than the role of aHCT as standard of care in
relapsed chemotherapy- sensitive patients, there is no
consensus regarding management of relapsed or re-
fractory DLBCL. Issues such as salvage regimen
choice and the role of R remain to be clarified, and
the results of the 2 phase III trials in progress are
eagerly awaited.Targeted drug development for relapsed/refrac-
tory DLBCL is evolving, and incorporating these
new agents into current treatment strategies needs to
be defined. Furthermore, additional but hitherto
unknown biologic markers in relapsed/refractory
DLBCL need to identified to improve our understand-
ing of disease mechanisms and foster further drug
development.
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